Market Checkup: September 17, 2013
Today's edition of Market Checkup focuses on EU drug approvals for struggling biotech Dendreon and big pharma company Sanofi, and a controversial dividend stock to watch.
More dividend stock ideas
One of the best parts of owning big pharma stocks is their attractive dividends, but smart investors know the importance of diversifying -- seeking high-yielding stocks from multiple industries. The Motley Fool's special free report "Secure Your Future With 9 Rock-Solid Dividend Stocks" outlines the Fool's favorite dependable dividend-paying stocks across all sectors. Grab your free copy by clicking here.
Note: At 6:38, the speaker incorrectly states that Sanofi had a partnership with biotech company Rigel. The Fool regrets the error.
The article Market Checkup: September 17, 2013 originally appeared on Fool.com.David Williamson has no position in any stocks mentioned. Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.